Results 141 to 150 of about 7,717 (219)
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. [PDF]
J Clin InvestWerr L, Boland J, Petersen J, Iglesias F, Höppner S, Bartenhagen C, Rosswog C, Hellmann AM, Kahlert Y, Hemstedt N, Ibruli N, Dammert MA, Decarolis B, Werner JM, Malchers F, Schramm K, Witt O, Beiske KH, Rognlien AGW, Gunnes MW, Langenberg KP, Molenaar J, Bernkopf M, Taschner-Mandl S, Hughes D, George SL, Chesler L, Schulte JH, Barone G, Capasso M, Surrey LF, Bagatell R, Masliah-Planchon J, Schleiermacher G, Grüll H, Westermann F, Schultheis AM, Büttner R, Henssen AG, Eggert A, Peifer M, Shukla NN, Simon T, Hero B, Reinhardt HC, Thomas RK, Fischer M. +46 moreeuropepmc +1 more sourceATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma. [PDF]
Cancer LettLorenzi F, Jostes S, Gao Q, Hutchinson JC, Tall J, Martins da Costa B, Cooke AJ, Rampling D, Ogunbiyi O, Barker K, Hughes D, Barone G, Barisa M, Bellini A, Hubank M, Schleiermacher G, Anderson J, Bernstein E, Chesler L, George SL. +19 moreeuropepmc +1 more sourceSequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy. [PDF]
Clin Cancer ResBobin C, Iddir Y, Butterworth C, Masliah-Planchon J, Saint-Charles A, Bellini A, Bhalshankar J, Pierron G, Combaret V, Attignon V, André N, Corradini N, Dumont B, Mansuy L, Khanfar C, Klein S, Briandet C, Plantaz D, Millot F, Thouvenin S, Aerts I, Ndounga-Diakou LA, Laghouati S, Abbou S, Jehanno N, Tissot H, Renault S, Baulande S, Raynal V, Bozec L, Bieche I, Delattre O, Berlanga P, Schleiermacher G. +33 moreeuropepmc +1 more sourceBright electron bunches from a plasma-wakefield accelerator with a steep density down-ramp. [PDF]
Nat CommunWood JC, Boulton L, Beinortaitė J, Björklund Svensson J, Bohlen S, Boyle G, Garland JM, Gonzalez Caminal P, Lindstrøm CA, Loisch G, Mewes SM, Parikh T, Peña F, Põder K, Schröder S, Thévenet M, Wesch S, Osterhoff J, D'Arcy R. +18 moreeuropepmc +1 more sourceAge Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. [PDF]
J Clin Oncol, 2020 Ambros IM, Tonini GP, Pötschger U, Gross N, Mosseri V, Beiske K, Berbegall AP, Bénard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh EF, Hogarty MD, Monclair TF, Holmes K, Valteau-Couanet D, Castel V, Tweddle DA, Park JR, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson ADJ, Ambros PF. +42 moreeuropepmc +1 more sourceBevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. [PDF]
J Clin OncolMoreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, Zwaan CM, Nysom K, Gerber N, Castellano A, Laureys G, Ladenstein R, Rössler J, Makin G, Murphy D, Morland B, Vaidya S, Thebaud E, van Eijkelenburg N, Tweddle DA, Barone G, Tandonnet J, Corradini N, Chastagner P, Paillard C, Bautista FJ, Gallego Melcon S, De Wilde B, Marshall L, Gray J, Burchill SA, Schleiermacher G, Chesler L, Peet A, Leach MO, McHugh K, Hayes R, Jerome N, Caron H, Laidler J, Fenwick N, Holt G, Moroz V, Kearns P, Gates S, Pearson ADJ, Wheatley K, Innovative Therapies for Children with Cancer (ITCC) and European Association for Neuroblastoma Research (SIOPEN). +47 moreeuropepmc +1 more sourceNeurological hospitalisations in childhood cancer survivors treated before 2001: findings from the French Childhood Cancer Survivor Study cohort. [PDF]
BMC NeurolRajaonera D, Bejarano-Quisoboni D, Grill J, Allodji RS, Pelletier-Fleury N, Journy N, Boussac M, Doz F, Vu-Bezin G, Zidane M, Schwartz B, Haddy N, Bolle S, El-Fayech C, Dufour C, Diallo I, Schleiermacher G, Fresneau B, de Vathaire F. +18 moreeuropepmc +1 more source